Confirmed cases of Ebola in the eastern Democratic Republic of Congo have surpassed 1,000, reaching 1,003 with 254 deaths, the country’s health ministry reported late on 21 June. The outbreak, declared on 15 May, has now recorded a mortality rate of 25.3 per cent and 100 recoveries, with 365 patients still in isolation or hospital care. Officials acknowledge that the true caseload is likely higher and that the peak of transmission has not yet been reached, making this the most severe first month of any Ebola outbreak on record.

The outbreak is driven by the rare Bundibugyo strain of the virus, for which no approved vaccines or specific therapies exist. Scientists from Uganda’s National Health Laboratory and Diagnostic Services and Congo’s National Institute of Biomedical Research confirmed last week that the strain originated from a new wildlife spillover event, ruling out any link to a previously undetected or dormant outbreak. This finding, combined with the absence of medical countermeasures, has complicated the response from the outset.

Response teams are active across the affected provinces of Ituri, North Kivu, and South Kivu, as well as in Uganda, where 19 cases and two deaths have been recorded. Contact tracing remains a critical weakness: authorities have achieved only 55 per cent coverage, far below the World Health Organization’s 90 per cent target, and more than 35,000 contacts remain to be traced. The outbreak’s index case has not been identified. At least 78 healthcare workers have fallen ill, 18 of them fatally, with many infections occurring in general clinics before the virus was recognised. Community resistance has further hindered containment; in Beni, residents armed with sticks and machetes stormed a treatment centre in protest over restrictions on traditional burial practices, and overcrowded isolation units have seen patients flee due to hunger.

The Africa Centres for Disease Control and Prevention has warned that without rapid control, the outbreak could surpass the 2014–2016 West African epidemic that killed over 11,000 people. Modelling by the United States Centers for Disease Control and Prevention similarly indicates a potential for record-breaking spread. In a notable clinical development, a US physician infected with the Bundibugyo strain was treated at Berlin’s Charité hospital with an experimental antibody-based drug and survived, though the therapy remains unapproved. Israeli health authorities are investigating a suspected case in a traveller returning from Congo. The next milestones to watch are improvements in contact-tracing coverage and any progress toward emergency use of candidate vaccines or therapeutics.